MedPath

Driving Performance of People With Parkinson's Using Autonomous In-Vehicle Technologies

Not Applicable
Completed
Conditions
Parkinson Disease
Registration Number
NCT04660500
Lead Sponsor
University of Florida
Brief Summary

For drivers with Parkinson's Disease (PD), autonomous in-vehicle technologies may help mitigate functional deficits, improve driving performance, decrease driving errors and enhance their ability to stay on the road. Using a pretest/posttest design the investigators will quantify the use of In-vehicle Information Systems (IVIS) and Advanced Driver Assistance Systems (ADAS) during driving to illustrate how IVIS and ADAS may affect driving, and provide recommendations to drivers with PD, the clinical community and industry.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
112
Inclusion Criteria
  1. Subjects diagnosed by a neurologist/ movement disorder specialist with clinically probable PD by Movement Disorders Society (MDS) criteria 25
  2. Has mild or moderate disease severity, based on the MDS-Unified Parkinson's Disease Rating Scale for motor symptoms (hereafter referred to as the UPDRS section 3) in the on state of medications (i.e., one hour of taking PD medications) and the Modified Hoehn and Yahr disease severity scale
  3. Is representative of one of two PD groups based on age, i.e., participants with symptom onset between 35-64 years of age (younger onset), or participants with symptom onset between ages 65- 85 years (older onset)
  4. Currently driving with a valid license
  5. Meets the Florida state requirement for visual acuity of at least 20/50 in one eye, if one eye is blind or 20/200 or worse the other eye must be 20/40 or better (20/40 in at least one eye) and field of vision (130 degrees or more)
  6. Lives independently in the community
  7. Proficient in reading/speaking English
  8. A Montreal Cognitive Assessment (MoCA) score of 20 or higher
Exclusion Criteria
  1. Concurrent neurological conditions (e.g., stroke, seizures; dementia)
  2. Severe psychiatric (e.g., psychoses/ significant anxiety) or physical conditions (e.g., missing limbs) precluding full participation
  3. Use of psychotropic medications having adverse effect on mental/physical functioning
  4. Severe, unpredictable motor fluctuations
  5. Severe sleep difficulties.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Type and number of driving errors1 year up to study completion

Type of driving errors include: speeding, lane maintenance and signaling on-road recorded by the evaluator, or via vehicle recorded kinematics and telematics (e.g., in-vehicle GPS to record speed).

Total number of driving errors1 year up to study completion

The evaluator will record the total number of driving errors by number and type (i.e., speeding, lane maintenance, and signaling) on a standardized data collection form.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UF Norman Fixel Institute for Neurological Diseases

🇺🇸

Gainesville, Florida, United States

UF Norman Fixel Institute for Neurological Diseases
🇺🇸Gainesville, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.